{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:29:39Z","timestamp":1771950579068,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clinthera.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T17:14:19Z","timestamp":1438449259000},"page":"1632-1642","source":"Crossref","is-referenced-by-count":37,"title":["Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success"],"prefix":"10.1016","volume":"37","author":[{"given":"Haruhiko","family":"Sugino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Amada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Ohgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusan","family":"Kostic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.07.006_bib1","series-title":"Dementia statistics","year":"2013"},{"key":"10.1016\/j.clinthera.2015.07.006_bib2","series-title":"Alzheimer\u05f3s Disease","year":"2013"},{"key":"10.1016\/j.clinthera.2015.07.006_bib3","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/j.jalz.2014.08.103","article-title":"2014 Report on the Milestones for the US National Plan to Address Alzheimer\u05f3s Disease","volume":"10","author":"Fargo","year":"2014","journal-title":"Alzheimers"},{"key":"10.1016\/j.clinthera.2015.07.006_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMc1305541","article-title":"Monetary costs of dementia in the United States","volume":"369","author":"Hurd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.07.006_bib5","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.jalz.2014.02.001","article-title":"2014 Alzheimer\u05f3s disease facts and figures","volume":"10","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31887\/DCNS.2000.2.2\/jmintzer","article-title":"Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist\u05f3s viewpoint","volume":"2","author":"Mintzer","year":"2000","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.clinthera.2015.07.006_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/gps.490","article-title":"The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer\u05f3s disease patients","volume":"17","author":"Beeri","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.clinthera.2015.07.006_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.31887\/DCNS.2009.11.2\/hbrodaty","article-title":"Family caregivers of people with dementia","volume":"11","author":"Brodaty","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.clinthera.2015.07.006_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.clinthera.2015.07.006_bib10","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","article-title":"Therapeutic approaches to Alzheimer\u05f3s disease","volume":"129","author":"Klafki","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2015.07.006_bib11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2125.2011.04134.x","article-title":"New pharmacological strategies for treatment of Alzheimer\u05f3s disease: focus on disease modifying drugs","volume":"73","author":"Salomone","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.07.006_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer\u05f3s disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2015.07.006_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5498\/wjp.v4.i4.72","article-title":"Pharmacological management of behavioral symptoms associated with dementia","volume":"4","author":"Madhusoodanan","year":"2014","journal-title":"World J Psychiatry"},{"key":"10.1016\/j.clinthera.2015.07.006_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/scientificamerican0811-16","article-title":"A dearth of new meds","volume":"305","author":"Kaitin","year":"2011","journal-title":"Sci Am"},{"key":"10.1016\/j.clinthera.2015.07.006_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial watch: phase II and phase III attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2015.07.006_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinthera.2015.07.006_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinthera.2015.07.006_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"Ekavali. A review on Alzheimer\u05f3s disease pathophysiology and its management: an update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.clinthera.2015.07.006_bib19","doi-asserted-by":"crossref","first-page":"837157","DOI":"10.1155\/2014\/837157","article-title":"Potential therapeutic strategies for Alzheimer\u05f3s disease targeting or beyond beta-amyloid: insights from clinical trials","volume":"2014","author":"Jia","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clinthera.2015.07.006_bib20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u05f3s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2015.07.006_bib21","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1007\/s10875-014-0041-4","article-title":"Clinical trials of intravenous immunoglobulin for Alzheimer\u05f3s disease","volume":"34","author":"Relkin","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.clinthera.2015.07.006_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u05f3s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.07.006_bib23","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer\u05f3s disease","volume":"129","author":"Engler","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2015.07.006_bib24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1302513","article-title":"Regulatory innovation and drug development for early-stage Alzheimer\u05f3s disease","volume":"368","author":"Kozauer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.07.006_bib25","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2174\/156720511797633250","article-title":"Mild cognitive impairment (MCI) - the novel trend of targeting Alzheimer\u05f3s disease in its early stages - methodological considerations","volume":"8","author":"Pater","year":"2011","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.clinthera.2015.07.006_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/alzrt143","article-title":"Dementia: a global health priority - highlights from an ADI and World Health Organization report","volume":"4","author":"Wortmann","year":"2012","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.clinthera.2015.07.006_bib27","series-title":"G8 Dementia Summit","year":"2013"},{"key":"10.1016\/j.clinthera.2015.07.006_bib28","series-title":"Alzheimer\u05f3s Association International Conference\u00ae convenes health leaders from around the world to discuss global action against dementia","year":"2014"},{"key":"10.1016\/j.clinthera.2015.07.006_bib29","unstructured":"World Health Organization. First WHO Ministerial Conference on Global Action Against Dementia. Vol 2015. Geneva, Switzerland: World Health Organization; 2015."},{"key":"10.1016\/j.clinthera.2015.07.006_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/14737175.2015.995638","article-title":"A pivotal moment in Alzheimer\u05f3s disease and dementia: how global unity of purpose and action can beat the disease by 2025","volume":"15","author":"Vradenburg","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2015.07.006_bib31","series-title":"Guidance for industry: Alzheimer\u2019s disease: developing drugs for the treatment of early stage disease","year":"2013"},{"key":"10.1016\/j.clinthera.2015.07.006_bib32","series-title":"Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease and other dementias. Vol EMA\/CHMP\/539931","first-page":"1","year":"2014"},{"key":"10.1016\/j.clinthera.2015.07.006_bib33","unstructured":"European Medicines Agency. Concept paper on need for revision of the guideline on medicinal products for the treatment of Alzheimer\u05f3s Disease and other dementias. EMA\/CHMP\/617734\/2013, 2013."},{"key":"10.1016\/j.clinthera.2015.07.006_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u05f3s disease: recommendations from the National Institute on Aging-Alzheimer\u05f3s Association workgroups on diagnostic guidelines for Alzheimer\u05f3s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jalz.2011.10.008","article-title":"Comparison of International Working Group criteria and National Institute on Aging-Alzheimer\u05f3s Association criteria for Alzheimer\u05f3s disease","volume":"8","author":"Visser","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib36","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/archneurol.2010.115","article-title":"Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer\u05f3s coordinating center database","volume":"67","author":"O\u05f3Bryant","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2015.07.006_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/alzrt158","article-title":"(18)F-florbetaben Abeta imaging in mild cognitive impairment","volume":"5","author":"Ong","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.clinthera.2015.07.006_bib38","first-page":"219","article-title":"Flutemetamol (18F): a beta-amyloid positron emission tomography tracer for Alzheimer\u05f3s and dementia diagnosis","volume":"50","author":"de Lartigue","year":"2014"},{"key":"10.1016\/j.clinthera.2015.07.006_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","article-title":"Beta-amyloid imaging with florbetaben","volume":"3","author":"Sabri","year":"2015","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.clinthera.2015.07.006_bib40","series-title":"Guideline on clinical evaluation of diagnostic agents","year":"2009"},{"key":"10.1016\/j.clinthera.2015.07.006_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fnins.2014.00327","article-title":"A review of beta-amyloid neuroimaging in Alzheimer\u05f3s disease","volume":"8","author":"Adlard","year":"2014","journal-title":"Front Neurosci"},{"key":"10.1016\/j.clinthera.2015.07.006_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jalz.2012.04.007","article-title":"Worldwide Alzheimer\u05f3s disease neuroimaging initiative","volume":"8","author":"Carrillo","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jalz.2010.03.008","article-title":"Update on the biomarker core of the Alzheimer\u05f3s Disease Neuroimaging Initiative subjects","volume":"6","author":"Trojanowski","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u05f3s disease: recommendations from the National Institute on Aging-Alzheimer\u05f3s Association workgroups on diagnostic guidelines for Alzheimer\u05f3s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u05f3s disease: recommendations from the National Institute on Aging-Alzheimer\u05f3s Association workgroups on diagnostic guidelines for Alzheimer\u05f3s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jalz.2011.04.003","article-title":"Revised criteria for diagnosis of Alzheimer\u05f3s disease: National Institute on Aging-Alzheimer\u05f3s Association diagnostic guidelines for Alzheimer\u05f3s disease","volume":"7","author":"Khachaturian","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib47","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u05f3s disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2015.07.006_bib48","series-title":"Accelerating Medicines Partnership[#,63]?>","volume":"Vol 2015","year":"2014"},{"key":"10.1016\/j.clinthera.2015.07.006_bib49","series-title":"11th Call for Proposals 2013","first-page":"1","year":"2013"},{"key":"10.1016\/j.clinthera.2015.07.006_bib50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jalz.2013.12.013","article-title":"International Alzheimer\u05f3s Disease Research Portfolio (IADRP) aims to capture global Alzheimer\u05f3s disease research funding","volume":"10","author":"Liggins","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.07.006_bib51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neurol.2013.07.017","article-title":"Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial","volume":"169","author":"Mills","year":"2013","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.clinthera.2015.07.006_bib52","doi-asserted-by":"crossref","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2015.07.006_bib53","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1586\/14737175.2014.945522","article-title":"Efficacy and safety studies of gantenerumab in patients with Alzheimer\u05f3s disease","volume":"14","author":"Panza","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2015.07.006_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fnagi.2014.00165","article-title":"beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer\u05f3s disease","volume":"6","author":"Menting","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.clinthera.2015.07.006_bib55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/WNN.0b013e318190cf75","article-title":"Clinical trial design issues in mild to moderate Alzheimer disease","volume":"21","author":"Knopman","year":"2008","journal-title":"Cogn Behav Neurol"},{"key":"10.1016\/j.clinthera.2015.07.006_bib56","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","article-title":"Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer\u05f3s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"13","author":"Wilkinson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2015.07.006_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.2015.995639","article-title":"Safety and clinical effects of EVP-6124 in subjects with Alzheimer\u05f3s disease currently or previously receiving an acetylcholinesterase inhibitor medication","volume":"15","author":"Deardorff","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2015.07.006_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u05f3s disease: a randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.clinthera.2015.07.006_bib59","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2015.07.006_bib60","unstructured":"Biogen Idec presents positive interim results from Phase 1B study of investigational Alzheimer\u05f3s disease treatment aducanumab (BIIB037) at 2015 AD\/PD\u2122 Conference [press release]. Cambridge, Mass: Biogen Idec; 2015. http:\/\/www.biogenidec.com\/press_release_details.aspx?ID=14712&Action=1&Newsld=2486&M=NewsV2&PID=619972015. Accessed March 21, 2015."},{"key":"10.1016\/j.clinthera.2015.07.006_bib61","unstructured":"Biogen Idec. Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-A\u03b2 IgG1 mAb) in Participants With Prodromal or Mild Alzheimer\u05f3s Disease. 2000\u20132015 ed. Bethesda, Md: National Library of Medicine; 2014."},{"key":"10.1016\/j.clinthera.2015.07.006_bib62","series-title":"Continuing America\u2019s Leadership: The Future of Medical Innovation for Patients","year":"2015"},{"key":"10.1016\/j.clinthera.2015.07.006_bib63","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov. Accessed February 28, 2015."},{"key":"10.1016\/j.clinthera.2015.07.006_bib64","unstructured":"Alzheimer Research Forum. http:\/\/www.alzforum.org. Accessed February 28, 2015."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815009340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815009340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T21:01:52Z","timestamp":1652994112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815009340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0149291815009340"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.07.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}